Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-03-27
2007-03-27
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S207000, C564S204000, C564S192000, C564S171000, C564S095000, C564S084000, C560S129000, C514S570000, C514S605000
Reexamination Certificate
active
10970242
ABSTRACT:
The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions.
REFERENCES:
patent: 4038415 (1977-07-01), Rajadhyaksha et al.
patent: 6444420 (2002-09-01), Mobley et al.
patent: 2003/0171412 (2003-09-01), Malamas et al.
patent: 2003/0181519 (2003-09-01), Mewshaw et al.
Mittal, S. et al.: Structure-Activity relationship of estrogens, receptor affinity and estrogen antagonist activity of certain (E) and (Z)-1,2,3-triaryl-2-propen-1-ones. J. Med. Chem. vol. 28, pp. 492-497, 1985.
Iyer, R. N. et al.: Anti-implantation effect of 2,3-diphenylacrylophenones. Indian J. of Exp. Biol. vol. 5, pp. 169-170, 1967.
Durani, N. et al.: Structure-Activity relationship of antiestrogens: A study using triarylbutenone, benzofuran, and triarylfuran analogues as models for triarylethylenes and triarylpropenones.J. Med. Chem. vol. 32, pp. 1700-1707, 1989.
Akema, T., et al., “On the relationship between noradrenergic stimulatory and GABAergic inhibitory systems in the control of luteinizing hormone secretion in female rats,”Neuroendocrinology, 1990, 52, 566-572.
Akhter, S.A., et al., “Targeting the receptor-Gqinterface to inhibit in vivo pressure overload myocardial hypertrophy,”Science, 1998, 280, 574-577.
Barkhem, T., et al., “Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists,”Molecular Pharmacology, 1998, 54, 105-112.
Battaini, F., “Protein kinase C isoforms as therapeutic targets in nervous system disease states,”Pharmacological Res., 2001, 44(5), 353-361.
Berendsen, H.H.G., et al., “Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats,”European J. of Pharmacology, 2001, 419, 47-54.
Björklund, A., et al., “Dopamine-containing systems in the CNS,”Elsevier Science Publishers B.V., 1984, Chapter 3, 55-122.
Carr, D.B., et al., “Serotonin receptor activation inhibits sodium current and dendritic excitability in prefrontal cortex via a protein kinase C-dependent mechanism,”J. of Neuroscience, 2002, 22(16), 6846-6855.
Chamberlain, M.C., et al., “Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101)-A Phase I study,”Arch Neurol., 1993, 50, 261-264.
Chambliss, K.L., et al., “Estrogen modulation of endothelial nitric oxide synthase,”Endocrine Reviews, 2002, 23(5), 665-686.
Dave, J.R., et al., “Evidence that β-endorphin binds to specific receptors in rat peripheral tissues and stimulates the adenylate cyclase-adenosine 3′, 5′-monophosphate system,”Endocrinology, 1985, 117(4), 1389-1396.
Demotes-Mainard, J., et al., “Estrogens modulate the responsiveness ofin vivorecorded striatal neurons to lontophoretic application of dopamine in rats: role of D1and D2receptor activation,”J. of Neuroendocrinology, 1990, 2(6), 825-832.
Doolan, C.M., et al., “Rapid non-genomic activation of cytosolic cyclic AMP-dependent protein kinase activity and [Ca2+]I by 17β-oestradiol in female rat distal colon,”British J. of Pharmacology, 2000, 129, 1375-1386.
Dubal, D.B., et al., “Estradiol modulates bcl-2 in cerebral ischemia: a potential role for estrogen receptors,”J. of Neuroscience, 1999, 19(15), 6385-6393.
Dubal, D.B., et al., Estrogen receptor α, not β, is a critical link in estrodiol-mediated protection against brain injury,PNAS, 2001, 98(4), 1952-1957.
Dutar, P., et al., “Pre- and postsynaptic GABABreceptors in the hippocampus have different pharmacological properties,”Neuron, 1988, 1, 585-591.
Ferin, M., et al., “The hypothalamic control of the menstrual cycle and the role of endogenous pioid peptides,”Recent Progress in Hormone Research, 1984, 40, 441-485.
Fitzpatrick, J.L., et al., “Estrogen-mediated neuroprotection against β-amyloid toxicity requires expression of estrogen receptor α or β and activation of the MAPK pathway,”J. of Neurochemistry, 2002, 82, 674-682.
Gu, Q., et al., “17β-estradiol potentiates kainite-induced currents via activation of the cAMP cascade,”J. of Neuroscience, 1996, 16(11), 3620-3629.
Gu, Q., et al., “Novel mechanism for non-genomic action of 17β-oestradiol on kainite-induced currents in isolated rat CA1 hippocampal neurons,”J. of Physiology, 1998, 506(3), 745-754.
Harrison, N.L., et al., “Structure-activity relationships for steroid interaction with the γ-aminobutyric acidAreceptor complex,”J. of Pharmacology & Experimental Therapeutics, 1987, 241(1), 346-353.
Herbison, A.E., “Estrogen regulation of GABA transmission in rate preoptic area,”Brain Research Bulletin, 1997, 44(4), 321-326.
Herbison, A.E., et al., “Distribution of estrogen receptor-immunoreactive cells in monkey hypothalamus: relationship to neurons containing luteinizing hormone-releasing hormone and tyrosine hydroxylase,”Neuroendocrinology, 1995, 61, 1-10.
Herbison, A.E., et al., “Erratum-Lack of detection of estrogen receptor-α transcripts in mouse gonadotropin-releasing hormone neurons,”Endocrinology, 2001, 142(1), 1 page.
Hökfelt, T., et al., “Distributional maps of tyrosine-hydroxylase-immunoreactive neurons in the rat brain,”Handbook of Chemical Neuroanatomy, Elsevier Science Publishers B.V., 1984, vol. 2, Chapter VI, 277-379.
Howell, S.B., et al., “Clinical applications of a novel sustained-release injectable drug delivery system: depoFoam™ technology,”The Cancer Journal, 2001, 7(3), 219-227.
Jacobowitz, O., et al., “Stimulation of specific types of Gs-stimulated adenylyl cyclases by phorbol ester treatment,”J. of Biological Chemistry, 1993, 268(6), 3829-3832.
Jarry, H., et al., “The inhibitory effect of β-endophin on LH release in ovariectomized rats does not involve the preoptic GABAergic system,”Experimental & Clinical Endocrinology & Diabetes, 1995, 103, 317-323.
Katre, N.V., et al., “Multivesicular liposome (DepoFoam) technology for the sustained delivery of insulin-like growth factor-1 (IGF-1),”J. of Pharmaceutical Sciences,, 1998, 87(11), 1341-1346.
Katzenellenbogen, J.A., et al., “Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers,”J. Steroid Biochem., 1985, 22(5), 589-596.
Kelly, M.J., et al., “Identification of estrogen-responsive LHRH neurons in guinea pig hypothalamus,”Brain Research Bulletin, 1984, 12, 399-407.
Kelly, M.J., et al., “Opioids hyperpolarize β-endorphin neurons via μ-receptor activation of a potassium conductance,”Neuoendocrinology, 1990, 52, 268-275.
Kelly, M.J., et al., “Rapid effects of estrogen to modulate G protein-coupled receptors via activation of protein kinase A and protein kinase C pathways,”Steroids, 1999, 64, 64-75.
Kelly, M.J., et al., “Electrophysiological analysis of neuroendocrine neuronal activity in hypothalamic slices,”Methods in Neurosciences, 1994, 20, 47-67.
Kelly, M.J., et al., “Estrogen suppresses μ-opioid-and GABAB-mediated hyperpolarization of hypothalamic arcuate neurons,”J. of Neuroscience, 1992, 12(7), 2745-2750.
Kelly, M.J., et al., “Estrogen modulation of G-protein-coupled receptors,”TEM, 1999, 10(9), 369-374.
Lagrange, A.H., et al., “Modulation of G-protein-coupled receptors by an estrogen receptor that activates protein kinase A,”Molecular Pharmacology, 1997, 51, 605-612
Kelly Martin J.
Qiu Jian
Ronnekleiv Oline K.
Scanlan Thomas S.
Tobias Sandra
Aulakh Charanjit S.
Oregon Health & Science University
The Regents of the University of California
Woodcock & Washburn LLP
LandOfFree
Development of new selective estrogen receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Development of new selective estrogen receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Development of new selective estrogen receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3749147